Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
Related to this article
The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma and Skin Cancer Data You May Have Missed at ESMO 2026
2
Iza-Bren Plus Pembrolizumab Shows Activity in Recurrent or Metastatic HNSCC
3
Sac-TMT Combo Improves PFS in First-Line PD-L1–Negative Nonsquamous NSCLC
4
Data Support Real-World Benefit of Cemiplimab in Advanced NSCLC Care
5